The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...

The FINEARTS-HF study included 46% women, showing finerenone's efficacy in reducing cardiovascular events in HFmrEF/HFpEF ...

A decision from the American Board of Medical Specialties will be made about a new cardiovascular board by this upcoming February.

The connection between brain, mental, and cardiovascular health needs considerable more attention, argues Maureen Hood, PhD, RN, Uniformed Services University.

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

Education and feedback for VHA pharmacists improved HF medication visits and prescribing, but personalized feedback did not ...

Posters presented at the American Heart Association Scientific Sessions included results that show how persistent disparities ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

Coming into CHEST 2024, Steven Nathan, MD, discusses how the largest unmet needs in the treatment and management of IPF and PAH include improving early diagnosis, addressing symptom management ...

The upcoming Greater Philadelphia Business Coalition on Health (GPBCH) 2024 Mental Health Summit aims to address the growing recognition among employers of the critical role mental health plays in ...